Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Interest Expenses (2016 - 2025)

Tg Therapeutics has reported Interest Expenses over the past 9 years, most recently at $6.5 million for Q4 2025.

  • Quarterly results put Interest Expenses at $6.5 million for Q4 2025, down 7.48% from a year ago — trailing twelve months through Dec 2025 was $26.7 million (up 10.63% YoY), and the annual figure for FY2025 was $26.7 million, up 11.23%.
  • Interest Expenses for Q4 2025 was $6.5 million at Tg Therapeutics, down from $6.7 million in the prior quarter.
  • Over the last five years, Interest Expenses for TGTX hit a ceiling of $10.8 million in Q3 2024 and a floor of $1.0 million in Q3 2021.
  • Median Interest Expenses over the past 5 years was $2.9 million (2022), compared with a mean of $4.0 million.
  • Peak annual rise in Interest Expenses hit 195.32% in 2025, while the deepest fall reached 37.95% in 2025.
  • Tg Therapeutics' Interest Expenses stood at $1.1 million in 2021, then skyrocketed by 165.25% to $2.9 million in 2022, then fell by 15.06% to $2.4 million in 2023, then soared by 190.46% to $7.1 million in 2024, then fell by 7.48% to $6.5 million in 2025.
  • The last three reported values for Interest Expenses were $6.5 million (Q4 2025), $6.7 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.